Screener
ImmunityBio, Inc. IBRX Impairment Charges
Discontinued — last reported Q4 '25
Impairment Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill.
The source filing: ImmunityBio, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 5:24 PM EST
- Fiscal year
- FY2025
- Accession
- 0001326110-26-000030
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Research and development – related parties | 10,684 | 7,914 | 9,348 |
| Selling, general and administrative | 147,180 | 165,801 | 126,136 |
| Selling, general and administrative – related parties | 2,823 | 2,982 | 3,484 |
| Impairment of intangible assets | — | — | 886 |
| Total operating costs and expenses | 369,315 | 358,927 | 362,872 |
| Loss from operations | (256,027) | (344,182) | (362,250) |
| Other income (expense), net: | |||
| Interest and investment income, net | 6,405 | 7,975 | 1,131 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is ImmunityBio, Inc.'s impairment charges?
- ImmunityBio, Inc. (IBRX) reported impairment charges of $0 in Q4 2025.
- What is the long-term trend for ImmunityBio, Inc.'s impairment charges?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s impairment charges has grown at a -100.0% compound annual growth rate (CAGR), from $681K to $0.
- What does impairment charges mean?
- Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.
Ask your AI about ImmunityBio, Inc.'s impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude